Published in Br J Cancer on May 01, 1998
Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med (2007) 1.89
GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst (2010) 1.68
Endothelial-mesenchymal transition of brain endothelial cells: possible role during metastatic extravasation. PLoS One (2015) 1.43
TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol (2005) 1.35
Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol (2004) 1.16
TGF-β-induced (TGFBI) protein in melanoma: a signature of high metastatic potential. J Invest Dermatol (2014) 1.13
CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration. Br J Cancer (2011) 1.12
Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. J Clin Invest (2014) 1.11
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol (2013) 0.99
Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place? Carcinogenesis (2010) 0.97
Efficient TGF-β/SMAD signaling in human melanoma cells associated with high c-SKI/SnoN expression. Mol Cancer (2011) 0.92
An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer. Anticancer Res (2009) 0.92
Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma. Ann Dermatol (2013) 0.92
The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis. Cancer Immunol Immunother (2011) 0.90
Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med (2011) 0.88
FKBP51 increases the tumour-promoter potential of TGF-beta. Clin Transl Med (2014) 0.88
Targeted agents for the treatment of metastatic melanoma. Onco Targets Ther (2012) 0.88
Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma. Clin Dev Immunol (2011) 0.86
HDAC6 deacetylase activity is required for hypoxia-induced invadopodia formation and cell invasion. PLoS One (2013) 0.84
Combining TGF-β1 knockdown and miR200c administration to optimize antitumor efficacy of B16F10/GPI-IL-21 vaccine. Oncotarget (2015) 0.78
Targeting transforming growth factor beta to enhance cancer immunotherapy. Curr Oncol (2006) 0.78
Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma. Cancer Immunol Immunother (2012) 0.78
Circulating TGF-β1 and VEGF and risk of cancer among liver transplant recipients. Cancer Med (2015) 0.78
Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity. J Clin Med (2016) 0.77
Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer. ISRN Dermatol (2013) 0.77
IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC. Clin Exp Metastasis (2003) 0.77
TGF-β1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma. Biol Res (2015) 0.76
Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2. Oncotarget (2016) 0.76
Expression of CD1a and Type-1 Polarization Are Dissociated in Human Monocyte-Derived Dendritic Cells. PLoS One (2015) 0.75
Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine. J Ovarian Res (2015) 0.75
The transforming growth factor-beta family. Annu Rev Cell Biol (1990) 10.62
Inflammatory and immunomodulatory roles of TGF-beta. Immunol Today (1989) 2.56
Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J (1987) 2.23
A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A (1990) 2.03
High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology (1996) 1.41
Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res (1994) 1.29
The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int J Cancer (1994) 1.25
Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol (1994) 1.19
Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol (1996) 1.14
Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat Med (1995) 1.09
Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J Immunother Emphasis Tumor Immunol (1996) 1.02
Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Res (1995) 0.91
Other functions, other genes: alternative activation of antigen-presenting cells. Immunity (1999) 4.15
A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J Virol (1994) 2.88
Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol (1998) 2.82
The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis (2001) 2.71
Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol (1998) 2.17
Alternative versus classical activation of macrophages. Pathobiology (1999) 2.14
Informatics and medicine--from molecules to populations. Methods Inf Med (2008) 2.13
A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology (2011) 2.09
Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma. Lancet (1997) 1.98
Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Scand J Immunol (2001) 1.86
Demographic, morphological, and clinical characteristics of 1289 patients with brain arteriovenous malformation. Stroke (2000) 1.79
Cerebral arteriovenous malformations and associated aneurysms: analysis of 305 cases from a series of 662 patients. Neurosurgery (2000) 1.75
Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol (1993) 1.73
The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol (2001) 1.67
Process quality and incidence of acute complications in a series of more than 230,000 outpatient colonoscopies. Endoscopy (2009) 1.56
[Flavonoids of Artemisia campestris, ssp. glutinosa]. Planta Med (1982) 1.55
Antibodies to hepatitis C virus. Lancet (1989) 1.47
Epidemiologic evidence for the role of melanocytic nevi as risk markers and direct precursors of cutaneous malignant melanoma. Results of a case control study in melanoma patients and nonmelanoma control subjects. J Am Acad Dermatol (1992) 1.47
Re: Exact tests of equivalence and efficacy with a non-zero lower bound for comparative studies by I. S. F. Chan, Statistics in Medicine, 17, 1403-1413 (1998) Stat Med (1999) 1.45
Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology (1997) 1.44
HIV-1 infection by artificial insemination. Lancet (1998) 1.44
Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95). J Invest Dermatol (1999) 1.43
Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europe. Yonsei Med J (1997) 1.43
[The optimult study concept - selective neoadjuvant chemoradiation therapy based on preoperative MRI]. Zentralbl Chir (2010) 1.40
Intravascular coagulation necrosis of the skin associated with cryofibrinogenemia, diabetes mellitus, and cardiolipin autoantibodies. J Am Acad Dermatol (1991) 1.39
[Combination of interferon-alpha with cytostatic drugs: a potentially successful therapeutic approach in metastatic melanoma]. Hautarzt (1992) 1.38
Oral hairy leukoplakia in 71 HIV-seropositive patients: clinical symptoms, relation to immunologic status, and prognostic significance. J Am Acad Dermatol (1996) 1.38
[Acute generalized exanthematous pustulosis, induced by nystatin]. Hautarzt (1998) 1.38
Outcomes of cryosurgery in keloids and hypertrophic scars. A prospective consecutive trial of case series. Arch Dermatol (1993) 1.36
Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res (2004) 1.33
Alterations of cell surfaces as a pathogenetic factor in psoriasis. Possible loss of contact inhibition of growth. Arch Dermatol (1973) 1.31
Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol (2009) 1.28
Meta-analysis of blood pressure tracking from childhood to adulthood and implications for the design of intervention trials. Acta Paediatr (2010) 1.28
Stent-protected angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy: SPACE2 - a three-arm randomised-controlled clinical trial. Int J Stroke (2009) 1.27
Classification of abnormal fundus autofluorescence patterns in the junctional zone of geographic atrophy in patients with age related macular degeneration. Br J Ophthalmol (2005) 1.27
Vestibular paroxysmia: diagnostic features and medical treatment. Neurology (2008) 1.27
Oral retinoids--present status. Br J Dermatol (1980) 1.26
Effect of partial targeted N-butyl-cyano-acrylate embolization in brain AVM. Acta Neurochir (Wien) (2002) 1.26
Cytokine regulation of proliferation and ICAM-1 expression of human dermal microvascular endothelial cells in vitro. J Invest Dermatol (1992) 1.25
Alternatively activated macrophages actively inhibit proliferation of peripheral blood lymphocytes and CD4+ T cells in vitro. Immunology (1997) 1.24
The monoclonal CD4 antibody M-T413 inhibits cellular infection with human immunodeficiency virus after viral attachment to the cell membrane: an approach to postexposure prophylaxis. Proc Natl Acad Sci U S A (1992) 1.24
Evidence for anti-inflammatory activities of oral synthetic retinoids: experimental findings and clinical experience. Br J Dermatol (1983) 1.24
Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus (1997) 1.23
Risk of invasive carcinoma in colorectal adenomas assessed by size and site. Int J Colorectal Dis (1997) 1.21
Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol (2007) 1.21
13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol (2000) 1.21
Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res (1995) 1.18
Clonal T-cell receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis in advanced cutaneous T-cell lymphoma: a critical evaluation. J Pathol (1999) 1.18
Androgen deficiency induces high turnover osteopenia in aged male rats: a sequential histomorphometric study. J Bone Miner Res (2000) 1.17
Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells in vitro. Int J Cancer (1997) 1.17
Fast light-regulated genes of Neurospora crassa. Nucleic Acids Res (1989) 1.16
Matting of hair: a multifactorial enigma. Dermatology (2000) 1.16
Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer (1995) 1.15
Dermal and epidermal types of erythema multiforme. A histopathologic study of 24 cases. Arch Dermatol (1974) 1.15
Differential expression of a gene signature for scavenger/lectin receptors by endothelial cells and macrophages in human lymph node sinuses, the primary sites of regional metastasis. J Pathol (2006) 1.14
Invasive carcinoma in colorectal adenomas: multivariate analysis of patient and adenoma characteristics. Endoscopy (1997) 1.14
Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1+3, MS-1+/-, 25F9-) in psoriatic dermis. Arch Dermatol Res (1996) 1.13
Sensitivity and specificity of commercial ELISA kits for screening anti-LAV/HTLV III. J Virol Methods (1987) 1.13
Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer (1995) 1.12
Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene (2006) 1.12
A Comprehensive Assessment Tool for Patient Registry Software Systems: The CIPROS Checklist. Methods Inf Med (2015) 1.12
Modelling the natural history of geographic atrophy in patients with age-related macular degeneration. Ophthalmic Epidemiol (2005) 1.11
Gastrointestinal chemosensation: chemosensory cells in the alimentary tract. Histochem Cell Biol (2012) 1.11
Inflammatory response after laparoscopic and conventional colorectal resections - results of a prospective randomized trial. Langenbecks Arch Surg (2000) 1.09
Hair destroying growth of Corynebacterium tenuis in the so-called trichomycosis axillaris. New findings from scanning electron microscopy. Arch Dermatol (1971) 1.09
Kaposi's sarcoma is an important risk factor for survival in HIV-infected patients independent of CD4+ cell count. AIDS (1999) 1.09
Gene expression in human peripheral blood mononuclear cells upon acute ischemic stroke. J Neurol (2008) 1.09
UV-induced squamous cell carcinoma--a role for antiapoptotic signalling pathways. Br J Dermatol (2009) 1.08
Neuroendocrine differentiation is a relevant prognostic factor in stage III-IV colorectal cancer. Eur J Gastroenterol Hepatol (2001) 1.08
Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release. FEBS Lett (2000) 1.08
Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance mutations among German seroconvertors. AIDS (1997) 1.07
The plasma unit membrane. Membrane mediated growth control and its failure in psoriasis. Br J Dermatol (1977) 1.07
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. Br J Cancer (2012) 1.07
The importance of individual nucleotides for the structure and function of rRNA molecules in E. coli. A mutagenesis study. FEBS Lett (1986) 1.06
Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. J Biol Chem (1998) 1.06
Risk related surveillance following colorectal polypectomy. Gut (2002) 1.06
Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol (2001) 1.05
Further evidence for Borrelia burgdorferi infection in morphea and lichen sclerosus et atrophicus confirmed by DNA amplification. J Invest Dermatol (1993) 1.04
Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses. J Infect Dis (1995) 1.04
The prognostic inhomogeneity of colorectal carcinomas Stage III: a proposal for subdivision of Stage III. Cancer (2001) 1.03
Non-specific lymphocyte transformation in vitro by nickel acetate. A possible source of errors in lymphocyte transformation test (LLT). J Invest Dermatol (1970) 1.02
Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. J Invest Dermatol (1990) 1.02
DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate (1993) 1.01
Automated analysis of digital fundus autofluorescence images of geographic atrophy in advanced age-related macular degeneration using confocal scanning laser ophthalmoscopy (cSLO). BMC Ophthalmol (2005) 1.01
[Acquired reactive perforating dermatosis. Successful treatment with allopurinol in 2 cases]. Hautarzt (1999) 1.01
[Beneficial effect of oral retinoid in psoriatic hyperproliferation. Autoradiographic studies on involved and non involved skin (author's transl)]. Arch Dermatol Res (1979) 1.00
A prospective randomized trial on heart rate variability of the surgical team during laparoscopic and conventional sigmoid resection. Arch Surg (2001) 1.00
Kaposi's sarcoma in AIDS. Multicentric angioneoplasia in early skin lesions. Am J Dermatopathol (1987) 1.00
Markers in cutaneous lupus erythematosus indicating systemic involvement. A multicenter study on 296 patients. Acta Derm Venereol (1997) 1.00
Androgen signal transduction and prostatic carcinoma. World J Urol (1994) 1.00
First case of HIV-1 subtype 0 infection in Germany. Infection (1996) 1.00
Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array. Int J Cancer (1999) 1.00
[Netherton's syndrome. Ichthyosis-like changes in the skin and trichorrhexis invaginata. Demonstration of pathologically changed cortex keratin in the hair]. Hautarzt (1971) 0.99
The German experience: the surgeon as a prognostic factor in colon and rectal cancer surgery. Surg Oncol Clin N Am (2000) 0.99